life sciences

Resonance Health - MRI for the masses

Stuart Roberts
Stuart Roberts NDF Research

In December 2016 NDF Research initiated coverage on Resonance Health (ASX: RHT), a Perth-based company which developed the world’s first non-invasive diagnostic for iron overload, an MRI-based test called FerriScan. This test, which gained both CE Mark and FDA approval in January 2005, has been the basis of a small... Show More

Dimerix's Phase 2 success for DMX-200 - an important potential new treatment option for kidney disease

Stuart Roberts
Stuart Roberts NDF Research

In August of last year NDF Research initiated on Dimerix (ASX: DXB), a Melbourne and Perth-based drug discovery company being built around new ways to identify drugs acting on G Protein-Coupled Receptors. Dimerix's platform is important because GPCRs are the target of a significant number of the world’s best-selling drugs.... Show More

ResApp Health - First major clinical study of ResAppDx reports important data

Stuart Roberts
Stuart Roberts NDF Research

In July 2016 NDF research initiated coverage on ResApp Health, a company developing a smartphone-based diagnostic for respiratory disease. ResApp has just reported important data from the first major clinical study of the ResAppDx, a smartphone-based diagnostic for respiratory disease which we have previously called the ResApp System. This Australian... Show More

Phylogica - In good company

Stuart Roberts
Stuart Roberts NDF Research

Sometimes it takes a while before good Life Sciences companies make it to being great Life Sciences companies. Phylogica is one such company. I've been following this Perth-based drug discovery operation since its 2005 IPO and I've always been impressed with the quality of the science and of the team,... Show More

Optiscan Imaging - The phoenix rises from the ashes

Stuart Roberts
Stuart Roberts NDF Research

Often Life Sciences companies do a ‘Rip Van Winkle’ - go to sleep for a long time, rather than just die. When they wake up again, such stocks can give investors a pleasant surprise. We believe Optiscan Imaging is one such ASX-listed Rip Van Winkle Life Science company. This Melbourne-based... Show More

Anatara Lifesciences ​- A good gut feeling

Stuart Roberts
Stuart Roberts NDF Research

Anatara Lifesciences is striking a blow against antibiotic resistance. The company is nearing the market with its first product, called Detach, a treatment for production animals such as cattle and pigs designed to reduce gastrointestinal disorders in these animals, thereby increasing meat yield. Anatara filed for Australian approval of Detach... Show More

Alcidion - Making hospitals smarter with Clinical Decision Support

Stuart Roberts
Stuart Roberts NDF Research

Medical error is now the third leading cause of death in the US. The Adelaide-based Alcidion Group, an emerging player in the US$100bn field of health informatics, has technology that can help reduce these deaths while making hospitals much more efficient. Alcidion is being built around an informatics platform called... Show More

Sirtex Medical - If you can keep your head, when all about you are losing theirs...

Stuart Roberts
Stuart Roberts NDF Research

Days like today make me wish I was back in stockbroking because Sirtex's 'Trading Update' has created the kind of contrarian play I love. Thanks to slower SIR-Spheres sales, Sirtex's constant currency EBITDA in 1H17 will fall 9-16%. As I write Sirtex stock is down 41%, making people think the... Show More

Resonance Health - World-leading MRI diagnostics

Stuart Roberts
Stuart Roberts NDF Research

Last week NDF Research initiated coverage on Resonance Health, a Perth-based company which over a decade ago developed the world’s first non-invasive diagnostic for iron overload, an MRI-based test called FerriScan. This test, approved in the US and Europe since 2005, has been the basis of a small but growing... Show More

Admedus - DNA vaccine Blue Sky, plus a growing core business

Stuart Roberts
Stuart Roberts NDF Research

Ian Frazer, of the University of Queensland, was Australian of the Year in 2006 because his research created Gardasil, the cervical cancer vaccine. Like all good Professors, Frazer hasn't stopped generating Next Big Thing ideas, and one of them is DNA vaccines to prompt a patient's own immune system to... Show More

LBT Innovations - Great new biotech productivity tool, potential company maker

Stuart Roberts
Stuart Roberts NDF Research

It was the kind of response ASX-listed Life Sciences companies wish they could have more often. The Adelaide-based LBT Innovations announced on Monday 10 October that it had gained FDA approval for APAS, short for 'Automated Plate Assessment System'. When the market heard the news it bid the stock up... Show More

Join the conversation

Dimerix - Favourable interim data with DMX-200

Stuart Roberts
Stuart Roberts NDF Research

Back in late August we initiated on Dimerix (ASX: DXB), a drug discovery company being built around new ways to identify highly valuable drug targets known as G Protein-Coupled Receptors. We've updated our coverage of Dimerix with a note on some recent data, which we think are very encouraging, from... Show More

Osprey gets ready to take off again

Stuart Roberts
Stuart Roberts NDF Research

A year ago it looked like disaster had struck Osprey Medical. In June 2014 the company had gained FDA approval for AVERT, a system that reduces the amount of contrast dye interventional cardiologists use during heart procedures. Contrast dye lets cardiologists see what's going on under X-Ray, but can be... Show More

100% Bullish on the New Zealand Life Sciences sector

Stuart Roberts
Stuart Roberts NDF Research

Are you bullish on New Zealand at the moment? If you are, you ought to check out what's going on in the country's emerging Life Sciences scene. This is the country that created Fisher & Paykel Healthcare as well as the A2 Milk Company, and, as Xero has shown us,... Show More

SomnoMed - An innovator's dillemma

Stuart Roberts
Stuart Roberts NDF Research

In 2009 ResMed, the pioneer of CPAP therapy for Obstructive Sleep Apnea, recorded US$921m in revenue and US$146m in NPAT. Business was booming, and it still is. FY16's revenue and NPAT were US$1.8bn and US$352m respectively. However seven years ago someone influential at ResMed must have read Clayton Christensen's masterpiece... Show More

Innate Immunotherapeutics - An MS drug candidate where the patients are saying good things

Stuart Roberts
Stuart Roberts NDF Research

Recently I was part of a 'Buy Hold Sell' video with Adam Allcock of Katana and Andy Gracey of Australian Ethical discussing this year's Bioshares conference and Life Science stocks we liked. One company Andy mentioned was the Auckland-based Innate Immunotherapeutics, whose MIS416 compound may help in 'Secondary Progressive' Multiple... Show More